Please provide your email address to receive an email when new articles are posted on . Belzupacap sarotalocan via suprachoroidal administration demonstrated positive interim phase 2 safety and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple ...
Please provide your email address to receive an email when new articles are posted on . WAILEA, Hawaii — The notion that all pigmentation in the eye is melanoma is a “rumor,” according to a speaker at ...
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today ...
BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which ...
Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024 Phase 2 End of Study Data Evaluating ...
Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback